Astonea Labs Ltd
Incorporated in 2017, Astonea Labs Ltd. is engaged in contract manufacturing of pharmaceutical and cosmetic products for companies[1]
- Market Cap ₹ 168 Cr.
- Current Price ₹ 160
- High / Low ₹ 185 / 118
- Stock P/E 36.2
- Book Value ₹ 50.9
- Dividend Yield 0.00 %
- ROCE 17.3 %
- ROE 35.4 %
- Face Value ₹ 10.0
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 30.4%
Cons
- Stock is trading at 3.14 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE SME IPO
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| 30.04 | 66.89 | 80.06 | 97.38 | |
| 24.21 | 59.75 | 68.14 | 82.09 | |
| Operating Profit | 5.83 | 7.14 | 11.92 | 15.29 |
| OPM % | 19.41% | 10.67% | 14.89% | 15.70% |
| 0.12 | 0.21 | 0.10 | 0.19 | |
| Interest | 1.58 | 2.34 | 2.97 | 3.83 |
| Depreciation | 3.79 | 3.93 | 3.67 | 4.58 |
| Profit before tax | 0.58 | 1.08 | 5.38 | 7.07 |
| Tax % | 56.90% | 38.89% | 24.35% | 24.33% |
| 0.25 | 0.67 | 4.07 | 5.35 | |
| EPS in Rs | 0.62 | 1.68 | 5.36 | 6.93 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 48% |
| TTM: | 22% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 178% |
| TTM: | 31% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 30% |
| Last Year: | 35% |
Balance Sheet
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 4.00 | 4.00 | 7.60 | 7.72 | 10.51 |
| Reserves | 3.49 | 4.16 | 4.26 | 10.69 | 42.96 |
| 29.53 | 35.99 | 42.39 | 53.33 | 39.05 | |
| 15.89 | 20.13 | 26.47 | 31.64 | 29.30 | |
| Total Liabilities | 52.91 | 64.28 | 80.72 | 103.38 | 121.82 |
| 21.39 | 20.75 | 21.75 | 25.03 | 26.08 | |
| CWIP | 0.00 | 0.00 | 2.10 | 5.01 | 6.27 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 31.52 | 43.53 | 56.87 | 73.34 | 89.47 | |
| Total Assets | 52.91 | 64.28 | 80.72 | 103.38 | 121.82 |
Cash Flows
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| -4.93 | -1.05 | 7.86 | 9.25 | |
| -3.31 | -3.08 | -8.35 | -11.14 | |
| 8.17 | 4.14 | -0.26 | 1.62 | |
| Net Cash Flow | -0.07 | 0.01 | -0.75 | -0.27 |
| Free Cash Flow | -8.26 | -4.17 | 0.42 | -1.51 |
| CFO/OP | -75% | -9% | 71% | 70% |
Ratios
Figures in Rs. Crores
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Debtor Days | 234.63 | 104.11 | 115.94 | 141.91 |
| Inventory Days | 136.35 | 121.40 | 160.81 | 160.68 |
| Days Payable | 273.08 | 128.11 | 148.90 | 143.66 |
| Cash Conversion Cycle | 97.89 | 97.41 | 127.85 | 158.93 |
| Working Capital Days | 98.30 | 32.79 | 28.22 | 29.31 |
| ROCE % | 8.01% | 16.97% | 17.30% |
Insights
In beta| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Actual Monthly Production - Capsules (Hard) Millions |
|
|||
| Actual Monthly Production - Ointments Millions |
||||
| Actual Monthly Production - Tablets Millions |
||||
| Actual Monthly Production - Toothpaste Millions |
||||
| Capacity Utilization - Capsules (Hard) % |
||||
| Capacity Utilization - Ointments % |
||||
| Capacity Utilization - Tablets % |
||||
| Capacity Utilization - Toothpaste % |
||||
| Installed Monthly Capacity - Capsules (Hard) Millions |
||||
| Installed Monthly Capacity - Ointments Millions |
||||
| Installed Monthly Capacity - Tablets Millions |
||||
| Installed Monthly Capacity - Toothpaste Millions |
||||
| Revenue Concentration - Top 10 Clients % |
||||
| Employee Count Number |
||||
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Acquisition
1d - Astonea Labs acquired 25.74% (52,00,000 shares) of Damaira for INR 6.25 Crore at INR 12.02/share.
-
Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association
27 Mar - EGM on 27 March 2026 approved new Articles of Association, effective 27.03.2026; available on website.
-
Approval Of Variation In The Objects Of The Initial Public Offer (IPO)
27 Mar - Shareholders approved reallocation of ₹6.25 crore IPO proceeds to acquire equity in Damaira; EGM 27-Mar-2026.
- Shareholder Meeting / Postal Ballot-Scrutinizer"s Report 27 Mar
-
Shareholder Meeting / Postal Ballot-Outcome of EGM
27 Mar - 27-Mar-2026 EGM approved IPO proceeds reallocation to acquire Damaira Pharma equity; material RPTs, Sec186 approvals, new AoA, director remuneration.
Business Verticals[1]
a) Own brands: ** Its own brand include "Glow Up" (cosmetics) and "Regero" (pharmaceuticals).
b) Contract Manufacturing**: It also engages in contract manufacturing for domestic and international clients, serving markets like the USA, Bolivia, Guatemala, Botswana, Iraq, and Yemen.